Delivery Order SPE2DB20D7066-SPE2DB25FC4JM
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $17,908 to AmerisourceBergen Drug Corp for the supply of HYPERRAB 300 Unit/mL vial 5mL, a rabies immunoglobulin product. This firm fixed-price, non-set-aside delivery order was awarded on August 20, 2025, with an ultimate completion date of September 11, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of HYPERRAB 300 Unit/ml Vial 3ml, a rabies immunoglobulin product, with a ceiling value of $20,416.56. This firm fixed-price delivery order, awarded on April 24, 2025, with an ultimate completion date of May 15, 2025, represents a non-competitive award under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a $1,790.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of HYPERRAB 300 Unit/mL vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-set-aside competitive award is scheduled for completion by October 6, 2025, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $10,744.80 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immune globulin product. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 11, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract utilizes no set-aside designation and represents a direct procurement of critical immunological...
- The Defense Logistics Agency awarded a delivery order valued at $8,895.79 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. This non-competed, firm fixed-price delivery order has a completion date of August 8, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $17,908.00 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML vial 5ML, a rabies immunoglobulin product used in post-exposure prophylaxis. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 19, 2025, and represents a continuation of the company's ongoing pharmaceutical supply relationship with federal healthcare systems. The work will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 16, 2025, for HYPERRAB 300 Unit/mL vial 5mL, a rabies immunoglobulin product, with a ceiling value of $5,372.40. This is a firm fixed price delivery order with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. The order will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters....
- The Defense Logistics Agency has awarded a delivery order valued at $3,581.62 to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin product used for post-exposure prophylaxis. The non-competitive delivery order is scheduled for completion by June 23, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. This award utilizes firm fixed pricing under a delivery order contract type, reflecting the standardized...
- The Defense Logistics Agency awarded a $10,744.80 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of HYPERRAB 300 Unit/mL Vial 5mL, a rabies immunoglobulin product used for post-exposure prophylaxis. This firm fixed-price, competitively awarded delivery order is scheduled for completion by August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract includes no set-aside designation,...
- The Defense Logistics Agency awarded a $1,732.55 delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/mL vials, with an ultimate completion date of August 11, 2025. This firm fixed-price contract represents a non-competitive, non-set-aside delivery order issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The place of performance is listed as Conshohocken,...
- SPE2DB20D7066Indefinite Delivery Contract
- SPE2DB20D7066-SPE2DB25FC4JMDelivery Order
The Defense Logistics Agency awarded a $3,581.62 delivery order to AmerisourceBergen Drug Corp for HYPERRAB 300 Unit/ML Vial 5ML, a rabies immunoglobulin pharmaceutical product. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for ultimate completion on September 8, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical federal medical procurement vendor that supplies a wide range of pharmaceutical products and medical supplies to Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's extensive portfolio of federal contract awards demonstrates its capability to fulfill diverse medical supply needs through open competition, including specialty medications, vaccines, and specialized medical commodities across multiple therapeutic domains. This delivery order for rabies immunoglobulin represents a routine pharmaceutical procurement supporting the military healthcare supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.6k | 8/15/25 |